SCHEMBL951497

SCHEMBL951497

CC1(C)OB(c2ccc(C(=O)N3CCOCC3)cc2)OC1(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHGDH O43175 1/20 0.55
HPGD P15428 6/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
ALDH1A1 P00352 2/20 0.52
MAPK1 P28482 1/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPT P10636 1/20 0.52
HTT P42858 1/20 0.52
AKR1C3 P42330 1/20 0.50
TSHR P16473 1/20 0.49
MLYCD O95822 1/20 0.48
POLB P06746 1/20 0.48
DNMT1 P26358 1/20 0.48
PTPN7 P35236 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
PKM P14618 1/20 0.48
HSP90AA1 P07900 2/20 0.46
HSP90AB1 P08238 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235445 0.88 HPGD (0.56) HPGDL3MBTL1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL24692234 0.88 HPGD (0.51) HPGDL3MBTL1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL21858993 0.88 L3MBTL3 (0.65) L3MBTL1ALDH1A1KDM4EEPHX2
SCHEMBL2239321 0.87 HPGD (0.59) HPGDL3MBTL1ALDH1A1MAPK1KDM4E
SCHEMBL578389 0.86 POLB (0.55) HPGDL3MBTL1TSHRPOLBKMT2A
SCHEMBL1804167 0.86 P4HB (0.45) HPGDSMN1; SMN2ALDH1A1HTTTSHR
SCHEMBL12621028 0.86 POLB (0.55) HPGDL3MBTL1TSHRPOLBKMT2A
SCHEMBL3718860 0.84 SIGMAR1 (0.53) HPGDL3MBTL1ALDH1A1EPHX2
Hydrochloric Acid SCHEMBL2209650 0.84 POLB (0.54) HPGDTSHRPOLBKMT2AEPHX2
SCHEMBL30765381 0.84 L3MBTL1 (0.55) HPGDL3MBTL1SMN1; SMN2KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737451-A1 NOVEL CARBOXAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Dong Wha Pharm. Co., Ltd. (KR) 2026-05-06 EP disclosed
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS MERCK SHARP & DOHME LLC (US) 2026-04-30 US disclosed
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 EP disclosed
US-20260085064-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF KARYOPHARM THERAPEUTICS INC (US) 2026-03-26 US disclosed
WO-2025128805-A1 A CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS MERCK SHARP & DOHME LLC (US) 2025-06-19 WO disclosed
US-12331040-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2025-06-17 US disclosed
EP-3321268-B1 BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY SCIENCE TECH & RES (SG) 2025-06-04 EP disclosed
US-20250170138-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2025-05-29 US disclosed
US-12275731-B2 Azaindole inhibitors of wild-type and mutant forms of LRRK2 DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-04-15 US disclosed
WO-2025003987-A1 NOVEL CARBOXAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 동화약품주식회사 2025-01-02 WO disclosed
EP-2215085-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2010-08-11 EP disclosed
WO-2009100171-A1 FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-13 WO disclosed
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 ASTRAZENECA AB (SE) 2009-05-07 US disclosed
US-20090111800-A1 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-30 US disclosed
WO-2009053737-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-04-30 WO disclosed
WO-2007124254-A2 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 WO disclosed
EP-1543003-B1 IMIDAZO¬1,2-A|PYRIDINES SMITHKLINE BEECHAM CORP (US) 2006-05-17 EP disclosed
US-20060004051-A1 Compounds DODIC NERINA 2006-01-05 US disclosed
US-20050245520-A1 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors DODIC NERINA 2005-11-03 US disclosed
US-20050234029-A1 Compounds DODIC NERINA 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245520-A1 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors SMAD2, SMAD3, ALK PHGDH 2926/4885HPGD 4054/4885L3MBTL1 1431/4885
US-12275731-B2 Azaindole inhibitors of wild-type and mutant forms of LRRK2 LRRK2, PARK7, GDI2 PHGDH 1934/4885HPGD 1441/4885L3MBTL1 223/4885
US-20250170138-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS AHR, ARNT, CYP1B1 PHGDH 2305/4885HPGD 240/4885L3MBTL1 3123/4885
US-20050234029-A1 Compounds SMAD3, SMAD2, ACVR1 PHGDH 3174/4885HPGD 4003/4885L3MBTL1 2054/4885
US-20090111800-A1 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD3B1, HSD17B1 PHGDH 223/4885HPGD 53/4885L3MBTL1 4228/4885
US-12331040-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof BCL6, MALT1, BTK PHGDH 2760/4885HPGD 2081/4885L3MBTL1 4402/4885
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS IL1A, IL1B, IL1RN PHGDH 4618/4885HPGD 2913/4885L3MBTL1 388/4885
US-20060004051-A1 Compounds SMAD3, SMAD2, TGFBR1 PHGDH 2835/4885HPGD 4433/4885L3MBTL1 1728/4885
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 MKI67, CCND3, CCND1 PHGDH 1646/4885HPGD 308/4885L3MBTL1 4648/4885
US-20260085064-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF BCL6, MALT1, BCL6B PHGDH 3787/4885HPGD 3137/4885L3MBTL1 3498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.